A carregar...
A synthetic CD8α:MyD88 co-receptor enhances CD8(+) T cell responses to weakly immunogenic and lowly expressed tumor antigens
T cell-based immunotherapies are a promising approach for patients with advanced cancers. However, various obstacles limit T cell efficacy, including suboptimal T cell receptor (TCR) activation and an immunosuppressive tumor environment. Here we developed a fusion protein by linking CD8α and MyD88 (...
Na minha lista:
| Publicado no: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5732881/ https://ncbi.nlm.nih.gov/pubmed/29055013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-0653 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|